Month: August 2025

CoinShares Announces Q2 2025 Results 29th August 2025 | SAINT HELIER, Jersey | CoinShares International Limited (“CoinShares” or “the Group”) (Nasdaq Stockholm: CS; US OTCQX: CNSRF), the leading European asset manager specialising in digital assets, has today published its results for the quarter ending 30th June 2025. Q2 2025 Financial HighlightsAsset Management fees of $30.0 million (Q2 2024: $28.3 million) Capital Markets gains/income of $11.3 million (Q2 2024: $14.6 million) Adjusted EBITDA of $26.3 million (Q2 2024: $25.5 million*) Treasury gain of $7.8 million (Q2 2024: $0.4 million loss) Net profit of $32.4 million (Q2 2024: $31.8 million) EPS (basic) for Q2 2025 of $0.49 (Q2 2024: $0.47) Total comprehensive income of $33.0 million (Q2 2024: $32.6 million)*Presented exclusive of FTX claim sale income and FlowBank impairment Jean-Marie...

RomReal hereby announces the results of the second quarter 2025 via the Report and an Investor presentation attached to this message. For further information, pls contact investors@romreal.comThis information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading ActAttachmentsRomReal Q2 2025 PresentationRomReal Q2 2025 Report

Financial Results and Operational Update for the Full Year Ended June 30, 2025 NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2025. Mesoblast Chief Executive Dr. Silviu Itescu said, “This has been a banner year for the Company, with achievement of FDA approval for Ryoncil®, the first and only FDA approved mesenchymal stromal cell (MSC) product in the United States and a successful commercial launch of the product for treatment of steroid-refractory acute graft-versus-host disease (SR-aGvHD) in pediatric patients aged 2 months and older (“children”).” ”We are working tirelessly to transform Mesoblast into a fast-paced commercial biotechnology...

VANCOUVER, British Columbia, Aug. 28, 2025 (GLOBE NEWSWIRE) — Central 1 Credit Union (Central 1) today reported its 2025 second quarter financials, reflecting strong results in the treasury line of business and investments for growth of the payments line of business. “Our results are showing steady performance for 2025, reflecting the renewed focus on our core payments and treasury lines of business since transferring digital banking operations to Intellect Design in the first quarter of 2025,” said Sheila Vokey, President & CEO of Central 1. “In the first half of the year, we’ve made meaningful investment and progress to evolve our business and to strengthen our position as a trusted aggregated services provider for Canadian credit unions and other financial service organizations.” Second quarter 2025 compared with the second...

All dollar amounts reflected in Canadian dollars unless otherwise stated VANCOUVER, British Columbia, Aug. 28, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, today announced its financial results for the three months ended June 30, 2025 (“Q2 2025”), and provided an update on recent corporate developments. Q2 2025 Financial HighlightsReported a net loss of $2,916,944. Research and development (R&D) expenses were $1,611,985, reflecting continued advancement of AI-powered drug candidates. General and administrative (G&A) expenses were $1,213,489 including investor & public relations and exchange-related fees. Operating expense cash burn (non-IFRS measure) was approximately...

Q2’25 revenue of $12.1 million, 99% YOY growth Full year revenue guidance of $45.5M – $47.5M CARLSBAD, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) — Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the second quarter ended June 30, 2025. “Our strong commercial performance was driven by the continued adoption of our highly differentiated AI-enabled aprevo® technology platform and growing recognition of its ability to deliver more favorable patient outcomes than legacy devices,” said Mike Cordonnier, Chairman and CEO of Carlsmed. “Building upon our momentum in personalized lumbar fusion surgery, in July we successfully completed the first personalized cervical spine surgery using our aprevo® technology...